Abstract
Objective To determine the effect of creatine monohydrate (CrM) supplementation to children with Duchenne muscular dystrophy through evaluation of their life style dependency, muscle state and lean bone mass and furthermore the role GM on oxidative stress and myofibrillar breakdown. To determine the effect of creatine monohydrate (CrM) supplementation to children with Duchenne muscular dystrophy through evaluation of their life style dependency, muscle state and lean bone mass and furthermore the role GM on oxidative stress and myofibrillar breakdown. Methods This is a single-blinded study which included two groups of patients (each = 15), the first group received CrM (0.10 g/kg/day) and group two received placebo. All patients were subjected to measurements including manual muscle testing using MRC scale and functional independence measures (FIM). Body composition is estimated using whole-body-energy X-ray absorptimetery. Muscular oxidative stress and myofibriller breakdown was evaluated through testing for serum level of malondialdhyde (MDA) level and 24 hours urine level of 3-methyle histadine. Results The results showed that CrM supplementation leads to statistical increase in bone mineral content (BMC) (p Conclusion We concluded from this work that CrM supplementation is well tolerated, with no side effects and increased BMC, improve muscle strength and ameliorate the increase in fat percentage. Moreover, decrease oxidative stress and myofibriller breakdown in Duchenne patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.